Inhibition of Ral GTPases using a stapled peptide approach

Jemima C. Thomas, Jonathan M. Cooper, Natasha S. Clayton, Chensu Wang, Michael A. White, Chris Abell, Darerca Owen, Helen R. Mott

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aberrant Ras signaling drives numerous cancers, and drugs to inhibit this are urgently required. This compelling clinical need combined with recent innovations in drug discovery including the advent of biologic therapeutic agents, has propelled Ras back to the forefront of targeting efforts. Activated Ras has proved extremely difficult to target directly, and the focus has moved to the main downstream Ras-signaling pathways. In particular, the Ras-Raf and Ras-PI3K pathways have provided conspicuous enzyme therapeutic targets that were more accessible to conventional drug-discovery strategies. The Ras-RalGEF-Ral pathway is a more difficult challenge for traditional medicinal development, and there have, therefore, been few inhibitors reported that disrupt this axis. We have used our structure of a Ral-effector complex as a basis for the design and characterization of α-helical-stapled peptides that bind selectively to active, GTP-bound Ral proteins and that compete with downstream effector proteins. The peptides have been thoroughly characterized biophysically. Crucially, the lead peptide enters cells and is biologically active, inhibiting isoform-specific RalB-driven cellular processes. This, therefore, provides a starting point for therapeutic inhibition of the Ras-RalGEF-Ral pathway.

Original languageEnglish (US)
Pages (from-to)18310-18325
Number of pages16
JournalJournal of Biological Chemistry
Volume291
Issue number35
DOIs
StatePublished - Aug 26 2016

Fingerprint

GTP Phosphohydrolases
Drug Discovery
Peptides
ral GTP-Binding Proteins
Biological Factors
Guanosine Triphosphate
Phosphatidylinositol 3-Kinases
Protein Isoforms
Therapeutics
Innovation
Enzymes
Pharmaceutical Preparations
Neoplasms
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Medicine(all)
  • Molecular Biology
  • Cell Biology

Cite this

Thomas, J. C., Cooper, J. M., Clayton, N. S., Wang, C., White, M. A., Abell, C., ... Mott, H. R. (2016). Inhibition of Ral GTPases using a stapled peptide approach. Journal of Biological Chemistry, 291(35), 18310-18325. https://doi.org/10.1074/jbc.M116.720243

Inhibition of Ral GTPases using a stapled peptide approach. / Thomas, Jemima C.; Cooper, Jonathan M.; Clayton, Natasha S.; Wang, Chensu; White, Michael A.; Abell, Chris; Owen, Darerca; Mott, Helen R.

In: Journal of Biological Chemistry, Vol. 291, No. 35, 26.08.2016, p. 18310-18325.

Research output: Contribution to journalArticle

Thomas, JC, Cooper, JM, Clayton, NS, Wang, C, White, MA, Abell, C, Owen, D & Mott, HR 2016, 'Inhibition of Ral GTPases using a stapled peptide approach', Journal of Biological Chemistry, vol. 291, no. 35, pp. 18310-18325. https://doi.org/10.1074/jbc.M116.720243
Thomas JC, Cooper JM, Clayton NS, Wang C, White MA, Abell C et al. Inhibition of Ral GTPases using a stapled peptide approach. Journal of Biological Chemistry. 2016 Aug 26;291(35):18310-18325. https://doi.org/10.1074/jbc.M116.720243
Thomas, Jemima C. ; Cooper, Jonathan M. ; Clayton, Natasha S. ; Wang, Chensu ; White, Michael A. ; Abell, Chris ; Owen, Darerca ; Mott, Helen R. / Inhibition of Ral GTPases using a stapled peptide approach. In: Journal of Biological Chemistry. 2016 ; Vol. 291, No. 35. pp. 18310-18325.
@article{20635d507324493896baff2de84d7fbf,
title = "Inhibition of Ral GTPases using a stapled peptide approach",
abstract = "Aberrant Ras signaling drives numerous cancers, and drugs to inhibit this are urgently required. This compelling clinical need combined with recent innovations in drug discovery including the advent of biologic therapeutic agents, has propelled Ras back to the forefront of targeting efforts. Activated Ras has proved extremely difficult to target directly, and the focus has moved to the main downstream Ras-signaling pathways. In particular, the Ras-Raf and Ras-PI3K pathways have provided conspicuous enzyme therapeutic targets that were more accessible to conventional drug-discovery strategies. The Ras-RalGEF-Ral pathway is a more difficult challenge for traditional medicinal development, and there have, therefore, been few inhibitors reported that disrupt this axis. We have used our structure of a Ral-effector complex as a basis for the design and characterization of α-helical-stapled peptides that bind selectively to active, GTP-bound Ral proteins and that compete with downstream effector proteins. The peptides have been thoroughly characterized biophysically. Crucially, the lead peptide enters cells and is biologically active, inhibiting isoform-specific RalB-driven cellular processes. This, therefore, provides a starting point for therapeutic inhibition of the Ras-RalGEF-Ral pathway.",
author = "Thomas, {Jemima C.} and Cooper, {Jonathan M.} and Clayton, {Natasha S.} and Chensu Wang and White, {Michael A.} and Chris Abell and Darerca Owen and Mott, {Helen R.}",
year = "2016",
month = "8",
day = "26",
doi = "10.1074/jbc.M116.720243",
language = "English (US)",
volume = "291",
pages = "18310--18325",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "35",

}

TY - JOUR

T1 - Inhibition of Ral GTPases using a stapled peptide approach

AU - Thomas, Jemima C.

AU - Cooper, Jonathan M.

AU - Clayton, Natasha S.

AU - Wang, Chensu

AU - White, Michael A.

AU - Abell, Chris

AU - Owen, Darerca

AU - Mott, Helen R.

PY - 2016/8/26

Y1 - 2016/8/26

N2 - Aberrant Ras signaling drives numerous cancers, and drugs to inhibit this are urgently required. This compelling clinical need combined with recent innovations in drug discovery including the advent of biologic therapeutic agents, has propelled Ras back to the forefront of targeting efforts. Activated Ras has proved extremely difficult to target directly, and the focus has moved to the main downstream Ras-signaling pathways. In particular, the Ras-Raf and Ras-PI3K pathways have provided conspicuous enzyme therapeutic targets that were more accessible to conventional drug-discovery strategies. The Ras-RalGEF-Ral pathway is a more difficult challenge for traditional medicinal development, and there have, therefore, been few inhibitors reported that disrupt this axis. We have used our structure of a Ral-effector complex as a basis for the design and characterization of α-helical-stapled peptides that bind selectively to active, GTP-bound Ral proteins and that compete with downstream effector proteins. The peptides have been thoroughly characterized biophysically. Crucially, the lead peptide enters cells and is biologically active, inhibiting isoform-specific RalB-driven cellular processes. This, therefore, provides a starting point for therapeutic inhibition of the Ras-RalGEF-Ral pathway.

AB - Aberrant Ras signaling drives numerous cancers, and drugs to inhibit this are urgently required. This compelling clinical need combined with recent innovations in drug discovery including the advent of biologic therapeutic agents, has propelled Ras back to the forefront of targeting efforts. Activated Ras has proved extremely difficult to target directly, and the focus has moved to the main downstream Ras-signaling pathways. In particular, the Ras-Raf and Ras-PI3K pathways have provided conspicuous enzyme therapeutic targets that were more accessible to conventional drug-discovery strategies. The Ras-RalGEF-Ral pathway is a more difficult challenge for traditional medicinal development, and there have, therefore, been few inhibitors reported that disrupt this axis. We have used our structure of a Ral-effector complex as a basis for the design and characterization of α-helical-stapled peptides that bind selectively to active, GTP-bound Ral proteins and that compete with downstream effector proteins. The peptides have been thoroughly characterized biophysically. Crucially, the lead peptide enters cells and is biologically active, inhibiting isoform-specific RalB-driven cellular processes. This, therefore, provides a starting point for therapeutic inhibition of the Ras-RalGEF-Ral pathway.

UR - http://www.scopus.com/inward/record.url?scp=84984679340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984679340&partnerID=8YFLogxK

U2 - 10.1074/jbc.M116.720243

DO - 10.1074/jbc.M116.720243

M3 - Article

VL - 291

SP - 18310

EP - 18325

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 35

ER -